Immunotherapy of Pancreatic Cancer

Stevenson, Ryan; Goodman, Martin; Saif, Muhammad Wasif

doi:10.1007/978-3-662-46410-6_12

Cited by 1 publication

(2 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It shows antitumour activities in vivo and in vitro in xenograft models. Furthermore in different studies, it has been demonstrated that Matuzumab induces ADCC in head and neck cell lines in vitro . As mentioned before, cetuximab and zalutumumab inhibit ligand binding whereas Matuzumab inhibits conformational changes and interferes the receptor‐associated transmembrane signalling pathways.…”

Section: Anit‐her1 Mabs and Derivativesmentioning

confidence: 90%

“…Furthermore in different studies, it has been demonstrated that Matuzumab induces ADCC in head and neck cell lines in vitro. [44][45][46][47][48] As mentioned before, cetuximab and zalutumumab inhibit ligand binding [49] whereas Matuzumab inhibits conformational changes and interferes the receptor-associated transmembrane signalling pathways. Following matuzumab administration mild rash has been reported in clinical trials.…”

Section: Zalutumumabmentioning

confidence: 92%

See 1 more Smart Citation

Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER

Moradi‐Kalbolandi

Hosseinzade

Salehi

et al. 2018

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives Monoclonal antibody-based of cancer therapy has been considered as one of the most successful therapeutic strategies for both haematologic malignancies and solid tumours in the last two decades. Epidermal growth factor receptor (EGFR) family signalling pathways play a key role in the regulation of cell proliferation, survival and differentiation. Hence, anti-EGFR family mAbs is one of the most promising approaches in cancer therapy. Key findings Here, recent advances in anti-EGFR mAb including approved or successfully tested in preclinical and clinical studies have been reviewed. Although we focus on monoclonal antibodies against the EGF receptor, but the mechanisms underlying the effects of EGFR-specific mAb in cancer therapy, to some extend the resistance to existing anti-EGFR therapies and some therapeutic strategies to overcome resistance such as combination of mAbs on different pathways are briefly discussed as well. Summary The EGFR family receptors, is considered as an attractive target for mAb development to inhibit their consecutive activities in tumour growth and resistance. However, due to resistance mechanisms, the combination therapies may become a good candidate for targeting EGFR family receptors.

show abstract

Section: Anit‐her1 Mabs and Derivativesmentioning

confidence: 90%